Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer

NCT06152523 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.

NCT NCT06152523
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06152523 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Phase 2
Overall status
Withdrawn
Start date
December 31, 2023
Completion date
December 31, 2028
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dmmr colorectal cancer, msi